img

Global Transthyretin Amyloidosis Drug Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Transthyretin Amyloidosis Drug Market Insights, Forecast to 2034

Transthyretin amyloidosis is a slowly progressive disease in which abnormal deposits of a protein called amyloid occur in the body's organs and tissues of the person. It is a progressive and fatal rare disease that can destroy nerve cells. It is often considered difficult to recognize and diagnose properly, and treatment is generally critical. However, the most common symptoms include heart failure, chronic diarrhea, weight loss, dry mouth, constipation, carpal tunnel syndrome, impaired kidney function, and floaters.
Global Transthyretin Amyloidosis Drug market is expected to reach to US$ 5449 million in 2024, with a positive growth of %, compared with US$ 5069 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Transthyretin Amyloidosis Drug industry is evaluated to reach US$ 8409.5 million in 2029. The CAGR will be 7.5% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Transthyretin Amyloidosis Drug market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Transthyretin Amyloidosis Drug market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Pfizer Inc
AstraZeneca
Prothena Corporation plc
Ionis Pharmaceuticals
BELLUS Health Inc
Alnylam Pharmaceuticals, Inc
Eidos Therapeutics, Inc
SOM BIOTECH
Abbvie, Inc
Bausch Health Companies Inc
Bristol Myers Squibb Company
GSK Plc
Merck KGaA
Sanofi
Segment by Type
Tafamidis
Patisiran
Inotersen
Other

Segment by Application


Hereditary Transthyretin Amyloidosis
Wild Transthyretin Amyloidosis

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Transthyretin Amyloidosis Drug plant distribution, commercial date of Transthyretin Amyloidosis Drug, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Transthyretin Amyloidosis Drug introduction, etc. Transthyretin Amyloidosis Drug Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Transthyretin Amyloidosis Drug
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Transthyretin Amyloidosis Drug Product Introduction
1.2 Market by Type
1.2.1 Global Transthyretin Amyloidosis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Tafamidis
1.2.3 Patisiran
1.2.4 Inotersen
1.2.5 Other
1.3 Market by Application
1.3.1 Global Transthyretin Amyloidosis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hereditary Transthyretin Amyloidosis
1.3.3 Wild Transthyretin Amyloidosis
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Transthyretin Amyloidosis Drug Sales Estimates and Forecasts 2018-2029
2.2 Global Transthyretin Amyloidosis Drug Revenue by Region
2.2.1 Global Transthyretin Amyloidosis Drug Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Transthyretin Amyloidosis Drug Revenue by Region (2018-2024)
2.2.3 Global Transthyretin Amyloidosis Drug Revenue by Region (2024-2029)
2.2.4 Global Transthyretin Amyloidosis Drug Revenue Market Share by Region (2018-2029)
2.3 Global Transthyretin Amyloidosis Drug Sales Estimates and Forecasts 2018-2029
2.4 Global Transthyretin Amyloidosis Drug Sales by Region
2.4.1 Global Transthyretin Amyloidosis Drug Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Transthyretin Amyloidosis Drug Sales by Region (2018-2024)
2.4.3 Global Transthyretin Amyloidosis Drug Sales by Region (2024-2029)
2.4.4 Global Transthyretin Amyloidosis Drug Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Transthyretin Amyloidosis Drug Sales by Manufacturers
3.1.1 Global Transthyretin Amyloidosis Drug Sales by Manufacturers (2018-2024)
3.1.2 Global Transthyretin Amyloidosis Drug Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Transthyretin Amyloidosis Drug in 2022
3.2 Global Transthyretin Amyloidosis Drug Revenue by Manufacturers
3.2.1 Global Transthyretin Amyloidosis Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Transthyretin Amyloidosis Drug Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Transthyretin Amyloidosis Drug Revenue in 2022
3.3 Global Key Players of Transthyretin Amyloidosis Drug, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Transthyretin Amyloidosis Drug Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Transthyretin Amyloidosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Transthyretin Amyloidosis Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Transthyretin Amyloidosis Drug, Product Offered and Application
3.8 Global Key Manufacturers of Transthyretin Amyloidosis Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Transthyretin Amyloidosis Drug Sales by Type
4.1.1 Global Transthyretin Amyloidosis Drug Historical Sales by Type (2018-2024)
4.1.2 Global Transthyretin Amyloidosis Drug Forecasted Sales by Type (2024-2029)
4.1.3 Global Transthyretin Amyloidosis Drug Sales Market Share by Type (2018-2029)
4.2 Global Transthyretin Amyloidosis Drug Revenue by Type
4.2.1 Global Transthyretin Amyloidosis Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Transthyretin Amyloidosis Drug Forecasted Revenue by Type (2024-2029)
4.2.3 Global Transthyretin Amyloidosis Drug Revenue Market Share by Type (2018-2029)
4.3 Global Transthyretin Amyloidosis Drug Price by Type
4.3.1 Global Transthyretin Amyloidosis Drug Price by Type (2018-2024)
4.3.2 Global Transthyretin Amyloidosis Drug Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Transthyretin Amyloidosis Drug Sales by Application
5.1.1 Global Transthyretin Amyloidosis Drug Historical Sales by Application (2018-2024)
5.1.2 Global Transthyretin Amyloidosis Drug Forecasted Sales by Application (2024-2029)
5.1.3 Global Transthyretin Amyloidosis Drug Sales Market Share by Application (2018-2029)
5.2 Global Transthyretin Amyloidosis Drug Revenue by Application
5.2.1 Global Transthyretin Amyloidosis Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Transthyretin Amyloidosis Drug Forecasted Revenue by Application (2024-2029)
5.2.3 Global Transthyretin Amyloidosis Drug Revenue Market Share by Application (2018-2029)
5.3 Global Transthyretin Amyloidosis Drug Price by Application
5.3.1 Global Transthyretin Amyloidosis Drug Price by Application (2018-2024)
5.3.2 Global Transthyretin Amyloidosis Drug Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Transthyretin Amyloidosis Drug Market Size by Type
6.1.1 US & Canada Transthyretin Amyloidosis Drug Sales by Type (2018-2029)
6.1.2 US & Canada Transthyretin Amyloidosis Drug Revenue by Type (2018-2029)
6.2 US & Canada Transthyretin Amyloidosis Drug Market Size by Application
6.2.1 US & Canada Transthyretin Amyloidosis Drug Sales by Application (2018-2029)
6.2.2 US & Canada Transthyretin Amyloidosis Drug Revenue by Application (2018-2029)
6.3 US & Canada Transthyretin Amyloidosis Drug Market Size by Country
6.3.1 US & Canada Transthyretin Amyloidosis Drug Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Transthyretin Amyloidosis Drug Sales by Country (2018-2029)
6.3.3 US & Canada Transthyretin Amyloidosis Drug Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Transthyretin Amyloidosis Drug Market Size by Type
7.1.1 Europe Transthyretin Amyloidosis Drug Sales by Type (2018-2029)
7.1.2 Europe Transthyretin Amyloidosis Drug Revenue by Type (2018-2029)
7.2 Europe Transthyretin Amyloidosis Drug Market Size by Application
7.2.1 Europe Transthyretin Amyloidosis Drug Sales by Application (2018-2029)
7.2.2 Europe Transthyretin Amyloidosis Drug Revenue by Application (2018-2029)
7.3 Europe Transthyretin Amyloidosis Drug Market Size by Country
7.3.1 Europe Transthyretin Amyloidosis Drug Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Transthyretin Amyloidosis Drug Sales by Country (2018-2029)
7.3.3 Europe Transthyretin Amyloidosis Drug Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Transthyretin Amyloidosis Drug Market Size
8.1.1 China Transthyretin Amyloidosis Drug Sales (2018-2029)
8.1.2 China Transthyretin Amyloidosis Drug Revenue (2018-2029)
8.2 China Transthyretin Amyloidosis Drug Market Size by Application
8.2.1 China Transthyretin Amyloidosis Drug Sales by Application (2018-2029)
8.2.2 China Transthyretin Amyloidosis Drug Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Transthyretin Amyloidosis Drug Market Size by Type
9.1.1 Asia Transthyretin Amyloidosis Drug Sales by Type (2018-2029)
9.1.2 Asia Transthyretin Amyloidosis Drug Revenue by Type (2018-2029)
9.2 Asia Transthyretin Amyloidosis Drug Market Size by Application
9.2.1 Asia Transthyretin Amyloidosis Drug Sales by Application (2018-2029)
9.2.2 Asia Transthyretin Amyloidosis Drug Revenue by Application (2018-2029)
9.3 Asia Transthyretin Amyloidosis Drug Sales by Region
9.3.1 Asia Transthyretin Amyloidosis Drug Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Transthyretin Amyloidosis Drug Revenue by Region (2018-2029)
9.3.3 Asia Transthyretin Amyloidosis Drug Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Market Size by Type
10.1.1 Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Market Size by Application
10.2.1 Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales by Country
10.3.1 Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Pfizer Inc
11.1.1 Pfizer Inc Company Information
11.1.2 Pfizer Inc Overview
11.1.3 Pfizer Inc Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Pfizer Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Inc Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 AstraZeneca Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 Prothena Corporation plc
11.3.1 Prothena Corporation plc Company Information
11.3.2 Prothena Corporation plc Overview
11.3.3 Prothena Corporation plc Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Prothena Corporation plc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Prothena Corporation plc Recent Developments
11.4 Ionis Pharmaceuticals
11.4.1 Ionis Pharmaceuticals Company Information
11.4.2 Ionis Pharmaceuticals Overview
11.4.3 Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Ionis Pharmaceuticals Recent Developments
11.5 BELLUS Health Inc
11.5.1 BELLUS Health Inc Company Information
11.5.2 BELLUS Health Inc Overview
11.5.3 BELLUS Health Inc Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 BELLUS Health Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 BELLUS Health Inc Recent Developments
11.6 Alnylam Pharmaceuticals, Inc
11.6.1 Alnylam Pharmaceuticals, Inc Company Information
11.6.2 Alnylam Pharmaceuticals, Inc Overview
11.6.3 Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Alnylam Pharmaceuticals, Inc Recent Developments
11.7 Eidos Therapeutics, Inc
11.7.1 Eidos Therapeutics, Inc Company Information
11.7.2 Eidos Therapeutics, Inc Overview
11.7.3 Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Eidos Therapeutics, Inc Recent Developments
11.8 SOM BIOTECH
11.8.1 SOM BIOTECH Company Information
11.8.2 SOM BIOTECH Overview
11.8.3 SOM BIOTECH Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 SOM BIOTECH Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 SOM BIOTECH Recent Developments
11.9 Abbvie, Inc
11.9.1 Abbvie, Inc Company Information
11.9.2 Abbvie, Inc Overview
11.9.3 Abbvie, Inc Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Abbvie, Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Abbvie, Inc Recent Developments
11.10 Bausch Health Companies Inc
11.10.1 Bausch Health Companies Inc Company Information
11.10.2 Bausch Health Companies Inc Overview
11.10.3 Bausch Health Companies Inc Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Bausch Health Companies Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Bausch Health Companies Inc Recent Developments
11.11 Bristol Myers Squibb Company
11.11.1 Bristol Myers Squibb Company Company Information
11.11.2 Bristol Myers Squibb Company Overview
11.11.3 Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Bristol Myers Squibb Company Recent Developments
11.12 GSK Plc
11.12.1 GSK Plc Company Information
11.12.2 GSK Plc Overview
11.12.3 GSK Plc Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 GSK Plc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 GSK Plc Recent Developments
11.13 Merck KGaA
11.13.1 Merck KGaA Company Information
11.13.2 Merck KGaA Overview
11.13.3 Merck KGaA Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Merck KGaA Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Merck KGaA Recent Developments
11.14 Sanofi
11.14.1 Sanofi Company Information
11.14.2 Sanofi Overview
11.14.3 Sanofi Transthyretin Amyloidosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Sanofi Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Sanofi Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Transthyretin Amyloidosis Drug Industry Chain Analysis
12.2 Transthyretin Amyloidosis Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Transthyretin Amyloidosis Drug Production Mode & Process
12.4 Transthyretin Amyloidosis Drug Sales and Marketing
12.4.1 Transthyretin Amyloidosis Drug Sales Channels
12.4.2 Transthyretin Amyloidosis Drug Distributors
12.5 Transthyretin Amyloidosis Drug Customers
13 Market Dynamics
13.1 Transthyretin Amyloidosis Drug Industry Trends
13.2 Transthyretin Amyloidosis Drug Market Drivers
13.3 Transthyretin Amyloidosis Drug Market Challenges
13.4 Transthyretin Amyloidosis Drug Market Restraints
14 Key Findings in The Global Transthyretin Amyloidosis Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Transthyretin Amyloidosis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Tafamidis
Table 3. Major Manufacturers of Patisiran
Table 4. Major Manufacturers of Inotersen
Table 5. Major Manufacturers of Other
Table 6. Global Transthyretin Amyloidosis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Transthyretin Amyloidosis Drug Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Transthyretin Amyloidosis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Transthyretin Amyloidosis Drug Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Transthyretin Amyloidosis Drug Revenue Market Share by Region (2018-2024)
Table 11. Global Transthyretin Amyloidosis Drug Revenue Market Share by Region (2024-2029)
Table 12. Global Transthyretin Amyloidosis Drug Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Transthyretin Amyloidosis Drug Sales by Region (2018-2024) & (K Units)
Table 14. Global Transthyretin Amyloidosis Drug Sales by Region (2024-2029) & (K Units)
Table 15. Global Transthyretin Amyloidosis Drug Sales Market Share by Region (2018-2024)
Table 16. Global Transthyretin Amyloidosis Drug Sales Market Share by Region (2024-2029)
Table 17. Global Transthyretin Amyloidosis Drug Sales by Manufacturers (2018-2024) & (K Units)
Table 18. Global Transthyretin Amyloidosis Drug Sales Share by Manufacturers (2018-2024)
Table 19. Global Transthyretin Amyloidosis Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Transthyretin Amyloidosis Drug Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Transthyretin Amyloidosis Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Transthyretin Amyloidosis Drug Price by Manufacturers 2018-2024 (US$/Unit)
Table 23. Global Transthyretin Amyloidosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Transthyretin Amyloidosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin Amyloidosis Drug as of 2022)
Table 25. Global Key Manufacturers of Transthyretin Amyloidosis Drug, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Transthyretin Amyloidosis Drug, Product Offered and Application
Table 27. Global Key Manufacturers of Transthyretin Amyloidosis Drug, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Transthyretin Amyloidosis Drug Sales by Type (2018-2024) & (K Units)
Table 30. Global Transthyretin Amyloidosis Drug Sales by Type (2024-2029) & (K Units)
Table 31. Global Transthyretin Amyloidosis Drug Sales Share by Type (2018-2024)
Table 32. Global Transthyretin Amyloidosis Drug Sales Share by Type (2024-2029)
Table 33. Global Transthyretin Amyloidosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Transthyretin Amyloidosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Transthyretin Amyloidosis Drug Revenue Share by Type (2018-2024)
Table 36. Global Transthyretin Amyloidosis Drug Revenue Share by Type (2024-2029)
Table 37. Transthyretin Amyloidosis Drug Price by Type (2018-2024) & (US$/Unit)
Table 38. Global Transthyretin Amyloidosis Drug Price Forecast by Type (2024-2029) & (US$/Unit)
Table 39. Global Transthyretin Amyloidosis Drug Sales by Application (2018-2024) & (K Units)
Table 40. Global Transthyretin Amyloidosis Drug Sales by Application (2024-2029) & (K Units)
Table 41. Global Transthyretin Amyloidosis Drug Sales Share by Application (2018-2024)
Table 42. Global Transthyretin Amyloidosis Drug Sales Share by Application (2024-2029)
Table 43. Global Transthyretin Amyloidosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Transthyretin Amyloidosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Transthyretin Amyloidosis Drug Revenue Share by Application (2018-2024)
Table 46. Global Transthyretin Amyloidosis Drug Revenue Share by Application (2024-2029)
Table 47. Transthyretin Amyloidosis Drug Price by Application (2018-2024) & (US$/Unit)
Table 48. Global Transthyretin Amyloidosis Drug Price Forecast by Application (2024-2029) & (US$/Unit)
Table 49. US & Canada Transthyretin Amyloidosis Drug Sales by Type (2018-2024) & (K Units)
Table 50. US & Canada Transthyretin Amyloidosis Drug Sales by Type (2024-2029) & (K Units)
Table 51. US & Canada Transthyretin Amyloidosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Transthyretin Amyloidosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Transthyretin Amyloidosis Drug Sales by Application (2018-2024) & (K Units)
Table 54. US & Canada Transthyretin Amyloidosis Drug Sales by Application (2024-2029) & (K Units)
Table 55. US & Canada Transthyretin Amyloidosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Transthyretin Amyloidosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Transthyretin Amyloidosis Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Transthyretin Amyloidosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Transthyretin Amyloidosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Transthyretin Amyloidosis Drug Sales by Country (2018-2024) & (K Units)
Table 61. US & Canada Transthyretin Amyloidosis Drug Sales by Country (2024-2029) & (K Units)
Table 62. Europe Transthyretin Amyloidosis Drug Sales by Type (2018-2024) & (K Units)
Table 63. Europe Transthyretin Amyloidosis Drug Sales by Type (2024-2029) & (K Units)
Table 64. Europe Transthyretin Amyloidosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Transthyretin Amyloidosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Transthyretin Amyloidosis Drug Sales by Application (2018-2024) & (K Units)
Table 67. Europe Transthyretin Amyloidosis Drug Sales by Application (2024-2029) & (K Units)
Table 68. Europe Transthyretin Amyloidosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Transthyretin Amyloidosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Transthyretin Amyloidosis Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Transthyretin Amyloidosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Transthyretin Amyloidosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Transthyretin Amyloidosis Drug Sales by Country (2018-2024) & (K Units)
Table 74. Europe Transthyretin Amyloidosis Drug Sales by Country (2024-2029) & (K Units)
Table 75. China Transthyretin Amyloidosis Drug Sales by Type (2018-2024) & (K Units)
Table 76. China Transthyretin Amyloidosis Drug Sales by Type (2024-2029) & (K Units)
Table 77. China Transthyretin Amyloidosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Transthyretin Amyloidosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Transthyretin Amyloidosis Drug Sales by Application (2018-2024) & (K Units)
Table 80. China Transthyretin Amyloidosis Drug Sales by Application (2024-2029) & (K Units)
Table 81. China Transthyretin Amyloidosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Transthyretin Amyloidosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Transthyretin Amyloidosis Drug Sales by Type (2018-2024) & (K Units)
Table 84. Asia Transthyretin Amyloidosis Drug Sales by Type (2024-2029) & (K Units)
Table 85. Asia Transthyretin Amyloidosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Transthyretin Amyloidosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Transthyretin Amyloidosis Drug Sales by Application (2018-2024) & (K Units)
Table 88. Asia Transthyretin Amyloidosis Drug Sales by Application (2024-2029) & (K Units)
Table 89. Asia Transthyretin Amyloidosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Transthyretin Amyloidosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Transthyretin Amyloidosis Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Transthyretin Amyloidosis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Transthyretin Amyloidosis Drug Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Transthyretin Amyloidosis Drug Sales by Region (2018-2024) & (K Units)
Table 95. Asia Transthyretin Amyloidosis Drug Sales by Region (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales by Type (2018-2024) & (K Units)
Table 97. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales by Type (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales by Application (2018-2024) & (K Units)
Table 101. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales by Application (2024-2029) & (K Units)
Table 102. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales by Country (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales by Country (2024-2029) & (K Units)
Table 109. Pfizer Inc Company Information
Table 110. Pfizer Inc Description and Major Businesses
Table 111. Pfizer Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. Pfizer Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Pfizer Inc Recent Developments
Table 114. AstraZeneca Company Information
Table 115. AstraZeneca Description and Major Businesses
Table 116. AstraZeneca Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. AstraZeneca Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. AstraZeneca Recent Developments
Table 119. Prothena Corporation plc Company Information
Table 120. Prothena Corporation plc Description and Major Businesses
Table 121. Prothena Corporation plc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Prothena Corporation plc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Prothena Corporation plc Recent Developments
Table 124. Ionis Pharmaceuticals Company Information
Table 125. Ionis Pharmaceuticals Description and Major Businesses
Table 126. Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Ionis Pharmaceuticals Recent Developments
Table 129. BELLUS Health Inc Company Information
Table 130. BELLUS Health Inc Description and Major Businesses
Table 131. BELLUS Health Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. BELLUS Health Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. BELLUS Health Inc Recent Developments
Table 134. Alnylam Pharmaceuticals, Inc Company Information
Table 135. Alnylam Pharmaceuticals, Inc Description and Major Businesses
Table 136. Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Alnylam Pharmaceuticals, Inc Recent Developments
Table 139. Eidos Therapeutics, Inc Company Information
Table 140. Eidos Therapeutics, Inc Description and Major Businesses
Table 141. Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 142. Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Eidos Therapeutics, Inc Recent Developments
Table 144. SOM BIOTECH Company Information
Table 145. SOM BIOTECH Description and Major Businesses
Table 146. SOM BIOTECH Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 147. SOM BIOTECH Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. SOM BIOTECH Recent Developments
Table 149. Abbvie, Inc Company Information
Table 150. Abbvie, Inc Description and Major Businesses
Table 151. Abbvie, Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 152. Abbvie, Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 153. Abbvie, Inc Recent Developments
Table 154. Bausch Health Companies Inc Company Information
Table 155. Bausch Health Companies Inc Description and Major Businesses
Table 156. Bausch Health Companies Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 157. Bausch Health Companies Inc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 158. Bausch Health Companies Inc Recent Developments
Table 159. Bristol Myers Squibb Company Company Information
Table 160. Bristol Myers Squibb Company Description and Major Businesses
Table 161. Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 162. Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 163. Bristol Myers Squibb Company Recent Developments
Table 164. GSK Plc Company Information
Table 165. GSK Plc Description and Major Businesses
Table 166. GSK Plc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 167. GSK Plc Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 168. GSK Plc Recent Developments
Table 169. Merck KGaA Company Information
Table 170. Merck KGaA Description and Major Businesses
Table 171. Merck KGaA Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 172. Merck KGaA Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 173. Merck KGaA Recent Developments
Table 174. Sanofi Company Information
Table 175. Sanofi Description and Major Businesses
Table 176. Sanofi Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 177. Sanofi Transthyretin Amyloidosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 178. Sanofi Recent Developments
Table 179. Key Raw Materials Lists
Table 180. Raw Materials Key Suppliers Lists
Table 181. Transthyretin Amyloidosis Drug Distributors List
Table 182. Transthyretin Amyloidosis Drug Customers List
Table 183. Transthyretin Amyloidosis Drug Market Trends
Table 184. Transthyretin Amyloidosis Drug Market Drivers
Table 185. Transthyretin Amyloidosis Drug Market Challenges
Table 186. Transthyretin Amyloidosis Drug Market Restraints
Table 187. Research Programs/Design for This Report
Table 188. Key Data Information from Secondary Sources
Table 189. Key Data Information from Primary Sources
List of Figures
Figure 1. Transthyretin Amyloidosis Drug Product Picture
Figure 2. Global Transthyretin Amyloidosis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Transthyretin Amyloidosis Drug Market Share by Type in 2022 & 2029
Figure 4. Tafamidis Product Picture
Figure 5. Patisiran Product Picture
Figure 6. Inotersen Product Picture
Figure 7. Other Product Picture
Figure 8. Global Transthyretin Amyloidosis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Transthyretin Amyloidosis Drug Market Share by Application in 2022 & 2029
Figure 10. Hereditary Transthyretin Amyloidosis
Figure 11. Wild Transthyretin Amyloidosis
Figure 12. Transthyretin Amyloidosis Drug Report Years Considered
Figure 13. Global Transthyretin Amyloidosis Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Transthyretin Amyloidosis Drug Revenue 2018-2029 (US$ Million)
Figure 15. Global Transthyretin Amyloidosis Drug Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 16. Global Transthyretin Amyloidosis Drug Revenue Market Share by Region (2018-2029)
Figure 17. Global Transthyretin Amyloidosis Drug Sales 2018-2029 ((K Units)
Figure 18. Global Transthyretin Amyloidosis Drug Sales Market Share by Region (2018-2029)
Figure 19. US & Canada Transthyretin Amyloidosis Drug Sales YoY (2018-2029) & (K Units)
Figure 20. US & Canada Transthyretin Amyloidosis Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 21. Europe Transthyretin Amyloidosis Drug Sales YoY (2018-2029) & (K Units)
Figure 22. Europe Transthyretin Amyloidosis Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 23. China Transthyretin Amyloidosis Drug Sales YoY (2018-2029) & (K Units)
Figure 24. China Transthyretin Amyloidosis Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Asia (excluding China) Transthyretin Amyloidosis Drug Sales YoY (2018-2029) & (K Units)
Figure 26. Asia (excluding China) Transthyretin Amyloidosis Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales YoY (2018-2029) & (K Units)
Figure 28. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 29. The Transthyretin Amyloidosis Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Transthyretin Amyloidosis Drug in the World: Market Share by Transthyretin Amyloidosis Drug Revenue in 2022
Figure 31. Global Transthyretin Amyloidosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Transthyretin Amyloidosis Drug Sales Market Share by Type (2018-2029)
Figure 33. Global Transthyretin Amyloidosis Drug Revenue Market Share by Type (2018-2029)
Figure 34. Global Transthyretin Amyloidosis Drug Sales Market Share by Application (2018-2029)
Figure 35. Global Transthyretin Amyloidosis Drug Revenue Market Share by Application (2018-2029)
Figure 36. US & Canada Transthyretin Amyloidosis Drug Sales Market Share by Type (2018-2029)
Figure 37. US & Canada Transthyretin Amyloidosis Drug Revenue Market Share by Type (2018-2029)
Figure 38. US & Canada Transthyretin Amyloidosis Drug Sales Market Share by Application (2018-2029)
Figure 39. US & Canada Transthyretin Amyloidosis Drug Revenue Market Share by Application (2018-2029)
Figure 40. US & Canada Transthyretin Amyloidosis Drug Revenue Share by Country (2018-2029)
Figure 41. US & Canada Transthyretin Amyloidosis Drug Sales Share by Country (2018-2029)
Figure 42. U.S. Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 43. Canada Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 44. Europe Transthyretin Amyloidosis Drug Sales Market Share by Type (2018-2029)
Figure 45. Europe Transthyretin Amyloidosis Drug Revenue Market Share by Type (2018-2029)
Figure 46. Europe Transthyretin Amyloidosis Drug Sales Market Share by Application (2018-2029)
Figure 47. Europe Transthyretin Amyloidosis Drug Revenue Market Share by Application (2018-2029)
Figure 48. Europe Transthyretin Amyloidosis Drug Revenue Share by Country (2018-2029)
Figure 49. Europe Transthyretin Amyloidosis Drug Sales Share by Country (2018-2029)
Figure 50. Germany Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 51. France Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 52. U.K. Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 53. Italy Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 54. Russia Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 55. China Transthyretin Amyloidosis Drug Sales Market Share by Type (2018-2029)
Figure 56. China Transthyretin Amyloidosis Drug Revenue Market Share by Type (2018-2029)
Figure 57. China Transthyretin Amyloidosis Drug Sales Market Share by Application (2018-2029)
Figure 58. China Transthyretin Amyloidosis Drug Revenue Market Share by Application (2018-2029)
Figure 59. Asia Transthyretin Amyloidosis Drug Sales Market Share by Type (2018-2029)
Figure 60. Asia Transthyretin Amyloidosis Drug Revenue Market Share by Type (2018-2029)
Figure 61. Asia Transthyretin Amyloidosis Drug Sales Market Share by Application (2018-2029)
Figure 62. Asia Transthyretin Amyloidosis Drug Revenue Market Share by Application (2018-2029)
Figure 63. Asia Transthyretin Amyloidosis Drug Revenue Share by Region (2018-2029)
Figure 64. Asia Transthyretin Amyloidosis Drug Sales Share by Region (2018-2029)
Figure 65. Japan Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 66. South Korea Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 67. China Taiwan Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 68. Southeast Asia Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 69. India Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Revenue Share by Country (2018-2029)
Figure 75. Middle East, Africa and Latin America Transthyretin Amyloidosis Drug Sales Share by Country (2018-2029)
Figure 76. Brazil Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 77. Mexico Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 78. Turkey Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 79. Israel Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 80. GCC Countries Transthyretin Amyloidosis Drug Revenue (2018-2029) & (US$ Million)
Figure 81. Transthyretin Amyloidosis Drug Value Chain
Figure 82. Transthyretin Amyloidosis Drug Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries